


EXPRESS MAIL CERTIFICATE

Date 5/15/02 Label No. CV028648268-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature



RECEIVED

MAY 21 2002

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESSIVE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

1600/2900

Customer No.:



07278

Docket No.: 1034/1F808US5

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter H. St. George-Hyslop; Paul E. Fraster

Serial No.: 09/689,159 Art Unit: 1647

Confirmation No.: 2656

Filed: October 12, 2000 Examiner: Robert S. Landsman

For: GENETIC SEQUENCES AND PROTEINS RELATED TO ALZHEIMER'S DISEASE

EXAMINER'S COURTESY COPY
OF PENDING CLAIMS

Box Patent Ext.
Assistant Commissioner for Patents
Washington, DC 20231

Sir:

73. An antibody which selectively binds a mammalian Presenilin protein having at least 63% overall amino acid sequence identity with a Presenilin 1 having an amino acid sequence as depicted in SEQ ID NO:2.

74: (Amended) The antibody as defined in claim 73, wherein the mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs:2, 4, 134, 136, or 138.

75. (Amended) The antibody as defined in claim 73, which selectively recognizes an amino acid sequence of at least six contiguous amino acid residues as depicted in SEQ ID NOs:2, 4, 134, 136, or or 138; or antigenic fragments.

76. (Amended) The antibody as defined in claim 75, wherein the antibody selectively recognizes amino acid residues 30-44, 109-123, 304-318, or 346-360 of SEQ ID NO:2.

77. The antibody as defined in claim 73, which is a monoclonal antibody.

78. The antibody as defined in claim 73, which is a humanized antibody.

79. A hybridoma for producing the antibody as defined in claim 73.

80. A method for detecting the presence of a mammalian Presenilin protein in a biological sample, the method comprising:

- (i) contacting the biological sample with an antibody as defined in claim 73,
- (ii) incubating the sample and the antibody under conditions to induce binding of the antibody to the sample to form a complex,
- (iii) separating the complex from the sample, and
- (iv) detecting the complex.

81. (Amended) The method as defined in claim 80, wherein the mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs: 2, 4, 134, 136, or 138.